These novel therapies , Semaglutide , represent a significant advancement in addressing type 2 diabetes and conceivably related disorders. They are classified as GLP-1 hormone agonists , signifying they to emulate the endogenous GLP-1 substance , boosting metabolic secretion and reducing food intake. While Semaglutide each operates somewhat similar